Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial

@inproceedings{Elmets2010ChemopreventionON,
  title={Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial},
  author={Craig A. Elmets and Jaye L. Viner and Alice P. Pentland and Wendy L Cantrell and Hui-Yi Lin and Howard E. Bailey and Sewon Kang and Kenneth G. Linden and Michael Heffernan and Madeleine Duvic and Ellen Richmond and B E Elewski and Asad Umar and Walter Bell and Gary G. Gordon},
  booktitle={Journal of the National Cancer Institute},
  year={2010}
}
BACKGROUND Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin cancers. We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for actinic keratoses, the premalignant precursor of nonmelanoma skin cancers, and for nonmelanoma skin cancers, including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs). METHODS A double-blind placebo-controlled randomized… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

Similar Papers

Loading similar papers…